Evidence map›Paper›PMID 32664107›Full record

ArticleMedicine2020

Household financial burden among multidrug-resistant tuberculosis patients in Guizhou province, China: A cross-sectional study.

Yun Wang, Edward B McNeil, Zhongfeng Huang, Ling Chen, Xiaolong Lu, Chengqiong Wang, Huijuan Chen, Virasakdi Chongsuvivatwong

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Yun WangDepartment of Health Service Management, School of Medicine and Health Management, Guizhou Medical University, Guiyang, Guizhou, China.ORCID 0000-0003-1625-098
Edward B McNeilEpidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Zhongfeng HuangDepartment of Tuberculosis, Guiyang Public Health Clinical Center, Guiyang.
Ling ChenDepartment of Respiratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi.
Xiaolong LuDepartment of Health Service Management, School of Medicine and Health Management, Guizhou Medical University, Guiyang, Guizhou, China.
Chengqiong WangDepartment of Respiratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi.
Huijuan ChenDepartment of Tuberculosis Prevention and Control, Guizhou Center for Disease Prevention and Control, Guiyang, Guizhou, China.
Virasakdi ChongsuvivatwongEpidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Guiyang Medical University · CNPrince of Songkla University · THZunyi Medical University · CNGuizhou Center for Disease Control and Prevention · CNShanghai Public Health Clinical Center · CN

Funding

TB/MDR-TB Research training and Capacity Strengthening for LMIC in Southeast Asia Phase II: Promotion of Diversity, Equity and Inclusion (DEI)D43TW009522 · FIC · PRINCE OF SONGKLA UNIVERSITY · PI Virasakdi Chongsuvivatwong · 2015 to 2026
$3.0M
FIC NIH HHS D43 TW009522
6 · The paper itself

Abstract

Multidrug-resistant tuberculosis (MDR-TB) threatens global public health. Poor access to health care due to financial hardship contributes to further transmission of the disease. The study aimed to:A cross-sectional study was conducted in 2 hospitals designated for MDR-TB from January to August 2018. Data were collected by interviewing eligible MDR-TB outpatients and reviewing the medical records. The magnitude of financial burden was documented by total cost and distribution of cost components. Catastrophic payments were measured by 2 indicators: catastrophic health expenditure (CHE) and catastrophic total costs (CTC), both of which were estimated by incidence and intensity. Their associated factors were determined using logistic regression models.Of 161 households affected by MDR-TB, the average total costs due to MDR-TB treatment in the first year was US$ 8266 and consisted of 72% direct medical costs, 5% direct non-medical costs and 23% indirect costs (income loss). Thirty seven percent of direct medical costs were covered by insurance. Overall, the incidence of CHE and CTC was 68.3% and 87.0%, respectively. Both incidence and intensity for the 2 defined catastrophic costs increased when a households income decreased. Five significant factors of catastrophic costs were low household income, absence of students in a family, hospital length of stay, male gender, and job/productivity loss.Households with MDR-TB patients shouldered a high financial burden which was mainly driven by direct medical costs and income loss in Guizhou. Greater catastrophic payments were associated with hospital length of stay and socioeconomic status, especially had a dose-response relationship with households income. Our findings suggest that financial and social protection of local policies for MDR-TB should be improved by preparing a uniform and comprehensive insurance package to cover sufficiently direct medical costs, and introducing social pro-poor assistance policies for risk families to protect them from financial hardship.

Indexed as

Cost of IllnessAdultChinaCross-Sectional StudiesFamily CharacteristicsFemaleHumansMaleMiddle AgedTuberculosis, Multidrug-Resistant

Identifiers

PMID32664107
PMCPMC7360282
OpenAlexW3041246093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.